BOARD-ADVISORS-AG
LEA Partners GmbH (LEA), a private equity and venture capital investor based in Karlsruhe, Germany, today announced the acquisition of Base-Net Informatik AG (Base-Net), a Swiss software provider leading in the field of credit and mortgage management.
Board Advisors Deutschland AG acted as the exclusive M&A advisor to the shareholders of Base-Net. The team of Christoph Löslein, Urs Niederberger, Felix Brokatzky and Federico Arcelli was able to successfully complete the transaction in less than five months.
"I am extremely pleased that, through the efforts of Board Advisors, we were able to find a new majority shareholder that is equally beneficial to the customers and employees of Base-Net Informatik AG. Despite a complex transaction structure, the advisors of Board Advisors had the mandate under control at all times, were able to successfully complete the project in a record-breaking time and to the full satisfaction of the shareholders."
Stefan Hermann, Founder and Chairman of the Board of Base-Net Informatik AG
Base-Net, headquartered in Sursee in the canton of Lucerne, was founded in 1994. With its WinCredit software it is the leading Swiss software provider in the field of credit and mortgage management. Currently, over 400 banks, insurance companies, pension funds and financial intermediaries use the company's software. In addition, Base-Net develops and operates a state-of-the-art platform for credit and mortgage refinancing.
"The market for credit management software is continuously growing and is highly attractive for us. Therefore, we are very pleased to have gained Base-Net, another leading and long-established company, for us. With this, we are taking another step in building a leading financial services platform in the DACH region."
Philipp Hertel, Partner at LEA
About Base-Net
Base-Net is the leading Swiss software provider in the field of credit and mortgage management. In addition to its loan management software, its solutions for refinancing and exchanges with the Swiss Pfandbriefbank are among the standard solutions in the Swiss financial sector. Founded in 1994 and based in Sursee, the company now serves around 400 banks and insurance companies. For more information, please visit www.basenet.ch .
About LEA Partners
LEA Partners is an entrepreneurial equity partner supporting founders and management teams in different stages of development to grow and achieve a leading market position. Based in Karlsruhe, one of the largest technology clusters in Europe, LEA Partners has managed investments in numerous technology companies since 2002. Following the merger of PROCAD, keytech and ACATEC in May 2021 and that of TAIFUN, M-Soft and PinnCalc in October 2021, the establishment of a buy-and-build platform in the financial services sector, which already includes the b+m Group in addition to Base-Net Informatik AG, represents the next significant transaction for the LEA B2B Tech funds focused on software companies from the DACH region. For more information, please visit www.leapartners.de .
About Board Advisors
Board Advisors is a Management Consulting and M&A advisory firm founded in 2005 by Christoph Löslein and is today headquarted in Freiburg im Breisgau. Board Advisors currently has own operations in Berlin, Zurich, Sursee, Basel, Nice, Munich and Manchester and has a network of international cooperation partners.
Board Advisors has in-depth expertise in the health and technology sectors and has successfully completed numerous business development projects, buy- & sell-side transactions and fundraising mandates in recent years. For further information, please visit www.boardadvisors.de .
View source version on businesswire.com: https://www.businesswire.com/news/home/20211103005562/en/
Link:
Social Media:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Andersen Consulting tilføjer samarbejdsfirmaet Codezilla7.12.2025 21:19:00 CET | Pressemeddelelse
Andersen Consulting styrker sine kompetencer inden for digital transformation gennem en samarbejdsaftale med Codezilla, et firma med hovedsæde i Rumænien, der udvikler specialtilpasset software. Codezilla specialiserer sig i at udvikle skræddersyede softwareprodukter, der løser forretningsmæssige udfordringer gennem en tværfaglig tilgang, som kombinerer softwareudvikling med dybdegående marketingekspertise. Med over 30 år på markedet fungerer firmaet som implementerings- og digital konsulentressource for reklamebureauer, samtidig med at de arbejder med en bred kundebase, herunder virksomheder inden for sundhedssektoren og medicinsk udstyr. Codezillas interne teams strækker sig over teknik, design og strategi og leverer omnichannel-løsninger til både regionale og globale kunder. "Vi tror på, at fantastisk software er resultatet af solid ingeniørkunst og disciplineret eksekvering," udtaler Sebastian Doroftei, administrerende direktør for Codezilla. "Vores samarbejde med Andersen Consulti
Hemato-Oncology Trials: AOP Health Presents New Results at Top Congress ASH7.12.2025 17:00:00 CET | Press release
AOP Health continues to advance its clinical research program in myeloproliferative neoplasms, a special group of rare blood cancers. The company, specialized in rare diseases, presented the results of two scientific investigations at the 67th American Society of Hematology Association (ASH) Annual Meeting 2025 held in Orlando, FL, USA. The results provide new insights in treatment strategies. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251207587915/en/ Dr. Martin Steinhart, CEO AOP Health; Photo credit: AOP Health/Studio Koekart ROP-ET and BESREMI PASS One of the clinical studies, ROP-ET, examined the use of ropeginterferon alfa-2b in people with essential thrombocythemia (ET), a disease in which the body produces too many platelets. The trial, a prospective, multicenter, single-arm phase III study, investigated the safety and efficacy of ropeginterferon alfa-2b in ET patients unable to receive available cytoreductive th
CoMotion GLOBAL 2025 Launches in Riyadh: Global Mobility Leaders Unite in Saudi Capital to Chart Urban Future7.12.2025 13:00:00 CET | Press release
Summit debuts Mayors in Motion initiative and CoMotion Urban Visionary Distinction as Riyadh showcases its rise as global mobility testbed Riyadh is rapidly becoming one of the world's most ambitious urban mobility laboratories, where next-generation technologies move from blueprint to real-world deployment on city streets at unprecedented scale. CoMotion GLOBAL 2025, the world's most influential gathering of urban mobility leaders, opens today in Riyadh for a three-day summit bringing together innovators from Africa, Asia, Europe, the Americas, and the Middle East. Running December 7-9, the event will explore how electrification, autonomy, AI-enabled transport, and giga-project urbanism are reshaping cities worldwide. The summit will spotlight everything from high-performance EVs and breakthrough autonomous fleets to emerging-market transport solutions and new mobility models, demonstrating how the Kingdom is opening new pathways for global mobility leadership. Strategic Partnerships
Deciphera Announces Oral Presentation of Positive Topline Results from Phase 2a Study of Sapablursen in Polycythemia Vera at the 67th American Society of Hematology (ASH) Annual Meeting6.12.2025 15:30:00 CET | Press release
Results from Phase 2a IMPRSSION study demonstrate sapablursen significantly reduced phlebotomy rate, controlled hematocrit and increased serum hepcidin Sapablursen was generally safe and well tolerated Results support further development of sapablursen in a Phase 3 study Deciphera Pharmaceuticals, a member of Ono Pharmaceutical Co., Ltd. (Headquarters: Osaka, Japan; President and COO: Toichi Takino; “Ono”), today announced the oral presentation of positive results from the Phase 2a IMPRSSION study of sapablursen in patients with polycythemia vera (PV) at the 67th American Society of Hematology (ASH) Annual Meeting, taking place December 6-9, 2025, in Orlando, FL. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251206361611/en/ The results were presented by Ionis Pharmaceuticals, who discovered and developed sapablursen and conducted the IMPRSSION study. In March 2025, Ionis and Ono entered into a license agreement in which On
Protagonist and Takeda Present Longer-Term Data at ASH 2025 Showing Rusfertide Delivers Durable Response and Hematocrit Control in Polycythemia Vera6.12.2025 15:30:00 CET | Press release
52-Week Results from the Phase 3 VERIFY Study of Rusfertide Demonstrated Sustained Hematocrit Control and Response, Defined by Absence of Phlebotomy Eligibility, with No New Safety SignalsThese Data Build on Positive 32-Week Primary Analysis from VERIFY, Which Met its Primary Efficacy Endpoint and All Four Key Secondary EndpointsPatients Crossing Over from Placebo to Rusfertide at 32 Weeks Achieved a Similar Response Rate to Those Initially Randomized to Rusfertide, with 77.9% Achieving Absence of Phlebotomy Eligibility Between Weeks 40-52Four-Year Results from the Combined REVIVE and Long-Term Extension THRIVE Study Demonstrated a 13-Fold Reduction in Annual Rate of Phlebotomies from Baseline Protagonist Therapeutics, Inc. (“Protagonist”) (NASDAQ:PTGX) and Takeda (TSE:4502/NYSE:TAK) announce that new 52-week results from the pivotal Phase 3 VERIFY study evaluating rusfertide in patients with polycythemia vera (PV) will be presented in an oral presentation at the 67th American Society
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom